Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH-D: Zepatier for HCV in Dialysis Patients
NCT03791814Phase 4Withdrawn
- Sponsor
- Einstein Healthcare Network
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir in hepatitis C virus infection, sponsored by Einstein Healthcare Network. Primary endpoint: HCV treatment-lag time at 12 weeks. Planned start Jan 2019; status: withdrawn.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03791814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791814.